A for-profit plasma donation company has suspended plasma collection at all of its Canadian clinics, citing a temporary halt in response to recent public scrutiny. The pause affects Grifols’ network of donation centers across the country, including facilities in multiple provinces.
The company did not specify a timeline for resuming operations or provide details on the concerns prompting the shutdown. The decision comes after heightened attention to the donation process and regulatory oversight within Canada, raising questions about safety, ethics, and governance in the plasma collection sector.
Grifols operates a series of donation centers that collect plasma for the production of therapies and other medical products. The temporary shutdown marks a significant interruption in the company’s Canadian activity and could impact patients who rely on plasma-derived medicines, as well as potential donors awaiting the opportunity to donate.
There was no immediate information on how this pause will affect ongoing research, current plasma inventories, or potential steps the company might take to address public concerns and regulatory requirements. Officials have not announced any changes to staffing or clinic operations beyond the cessation of plasma collection.
Observers note that plasma collection firms are under increasing scrutiny over safety, donor eligibility, compensation policies, and the transparency of operations. Authorities in Canada have previously examined the industry’s practices, and industry representatives have indicated a commitment to compliance with applicable health and safety standards.
Grifols has not released a public timeline for resuming plasma collection or elaborated on the specific concerns driving the shutdown. The company’s Canadian clinics remain closed to plasma collection for the foreseeable future, pending further notice.
